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Advances in molecular diagnostics in the last 15 years have changed the landscape of Lynch syndrome. It is now quite common to identify a germline mutation in one of the mismatch repair genes. The most common mutations are those in MLH1 and MSH2. 4 Microsatellite instability testing and immunohistochemistry are useful tools to determine whether a patient is a candidate for testing for mutations in the mismatch repair genes. 4, 11 Advances in molecular genetics, particularly in the identification of cancer-causing mutations in germ cells, have made it possible to establish whether patients are at high risk of hereditary cancers. In this review, we discuss some of the distinguishing features of hereditary colorectal cancer syndromes and outline the role that primary care physicians play in the detection of hereditary colorectal cancer syndromes and the care of affected patients.
A recently identified mutation: MYH
The MYH gene plays an active role in protecting genomic integrity during transcription. Although most hereditary cancer syndromes have an autosomal dominant inheritance pattern, MYH mutations are autosomal recessive, which means that a mutation must occur in both alleles of the gene in order for disease to develop. The effect of a monoallelic mutation in MYH is unclear. There is phenotypic overlap between milder, attenuated forms of familial adenomatous polyposis and MYH-associated polyposis. However, MYH-associated polyposis typically results in a different pattern of extracolonic cancers, including breast cancer, 12 sebaceous adenocarcinoma and endometrial cancer. 13 The possibility of sebaceous adeno-carcinoma in this syndrome overlaps with Muir-Torre syndrome, which is a variant of Lynch syndrome. 14, 15 Expanded testing, screening and management criteria are being developed for MYH-associated polyposis. MYH mutation testing is indicated for patients with multiple colonic adenomas who do not have an APC mutation. Based on their study that included 453 patients with multiple colorectal adenomata and no APC mutation, Olschwang and coworkers 16 suggested an early screening program, beginning between ages 25 and 30, that includes endoscopy of the upper digestive tract and colorectum every 2 years.
As with any hereditary colorectal cancer syndrome, screening and management recommendations are based on the natural history of the disorder along with the results of genetic testing (Table 1, Table 2 ).
Family history
A family history that includes most, if not all, relevant details can be collected at the time of patient intake or registration by use of a structured questionnaire that can be reviewed and addressed during the clinic visit. An alternative to a printed questionnaire is the online tool for recording family medical history provided by the United States Department of Health and Human Services (www.hhs.gov/familyhistory/) as part of the United States Surgeon General's Family History Initiative. The suspicion of a hereditary cancer syndrome often results from recognition of a familial pattern of disease, such as a constellation of early colorectal, genitourinary, breast and selected types of other cancers. 20 Ideally, the patient's family history will include information about cancers of all anatomic sites, with approximate ages of onset, for the patient's first-degree relatives (parents, siblings, children) and, whenever possible, seconddegree relatives (maternal and paternal aunts, uncles and grandparents). Figure 2 shows the family members who should, whenever possible, be included in this modified nuclear pedigree. Older family members will have often passed the cancer risk age and, therefore, will be more genetically informative.
Referral to a geneticist or cancer centre
Referral to a medical geneticist or a hereditary cancer centre can be made at any time during the family workup process, depending on the complexity of the clinical or genetic problem, the physician's individual expertise and the resources available. The rates of referral for DNA testing for cancercausing mutations are low throughout the world, even among patients with a family history of cancer. For example, Murff and colleagues 22 reported that, of 6 candidates at high risk for breast cancer, only 1 was referred for BRCA testing. Guttmacher and colleagues 23 reported that only 17% of patients who would be considered as candidates for genetic testing were referred for testing. It is unfortunate that so many patients are not receiving the many benefits of molecular genetic testing. Knowledgeable primary care physicians are key to improving these numbers.
Comprehensive family pedigree
If a hereditary cancer syndrome is suspected, a comprehensive family history for cancer can supplement a patientreported family history. Patient-reported family histories for cancer are accurate and valuable for assessing the risk of breast cancer and colorectal cancer but are less accurate for more rare types of cancer. 24 Primary care physicians may wish to construct the more detailed comprehensive family history, but this is more commonly done by a genetic counsellor or a medical geneticist after referal.
The comprehensive family pedigree incorporates all of the available cancer findings in the family, including cancer of all anatomic sites with age of onset 25 and pathology documentation (if available) as well as pertinent noncancer phenotypic features, such as perioral pigmentation in Peutz-Jeghers syndrome, multiple colonic adenomas in familial adenomatous polyposis, a paucity of polyps in its attenuated familial adenomatous polyposis counterpart, and the presence of sebaceous adenomas, sebaceous carcinomas and multiple keratoacanthomas in MuirTorre syndrome (a variant of Lynch syndrome). 4, 26 Table 1 shows the characteristics of hereditary polyposis syndromes, and those of Lynch syndrome are listed in Box 1.
Genetic testing
It is essential to determine which patients need to be tested for hereditary cancer syndromes. 27 We recommend that the following criteria be met before a patient is referred to a medical geneticist or a hereditary cancer centre or before genetic testing: a family history consistent with the hereditary cancer syndrome of concern; a mutation for which testing exists that has been identified as causal to the syndrome; availability of comprehensive genetic counseling, 28 with risks and benefits understood to have truly informed patient consent; and the existence of useful surveillance or management options, or both, for carriers of the mutation that would affect the patient's care.
The most genetically informative family member is one with an early-onset syndrome cancer who is in the patient's direct line of hereditary descent (e.g., a parent, sibling or child affected by a syndrome cancer). This family member would be the most likely family member to carry the family's deleterious mutation, if there is one present in the family. If a mutation is identified in a likely carrier, it is possible for other family members to undergo "mutation-specific testing," which has lesser cost and higher accuracy than the initial testing needed to identify the specific mutation.
Once a family's cancer-causing mutation has been identified, it is necessary to decide which other family members should receive mutation-specific testing. Considerations include whether cancer-causing mutation is known to segregate in the family; whether the mutation has been identified in a candidate family member; whether the individual patient is at high risk of cancer because of his or her position in the pedigree or has a syndrome-associated cancer; and whether the patient has a cancer syndrome stigmata (phenotype) (e.g., multiple polyposis in familial adenomatous polyposis).
Patients
The Colorectal Cancer Coalition's website also has information for patients (http://fightcolorectalcancer.org /awareness /patients/prevention/risk). When possible, family members should be given the opportunity to participate in a family information service, 29 which can be effective in enhancing cancer control through its informal group educational and therapeutic benefits.
Surveillance and management
Once Lynch syndrome has been diagnosed, medical management involves a highly targeted screening and management program, which is based on the syndrome's natural history (Box 1). Table 3 shows the level of evidence for the most common screening and management modalities. 30 Lindor and colleagues 30 note that evidence from many studies is insufficient to recommend for or against most of these practices. It is therefore necessary to base recommendations, at least in part, on the characteristics and natural history of the disorder.
Colonoscopic screening has been shown to significantly improve survival among carriers of a mutation associated with Lynch syndrome. 31, 32 Lindor and colleagues 30 reported that the available evidence strongly supports colonoscopic surveillance for patients with Lynch syndrome, and they recommended this procedure every 1-2 years, starting between the ages of 20 and 25. Those with a mutation in MSH6 should start screening at age 30. Features of Lynch syndromeassociated colorectal cancer that are addressed by these recommendations include early age of cancer onset, accelerated carcinogenesis of adenomas into carcinomas, and predilection to cancer of the proximal colon (about 70% of Lynch syndrome-related colorectal cancers occur in the right colon, which is not accessed through sigmoidoscopy). 4, 7 There is continuing research into improvements in colonoscopic detection of polyps and adenomas, such as chromoscopic colonoscopy 33, 34 and the use of narrow band imaging. 35 Lindor and colleagues 30 recommend subtotal colectomy for patients with Lynch syndrome who have colorectal cancer, and they also recommend urinalysis with cytology beginning between age 25 and 35.
Following colorectal cancer, the second most frequent cancer in Lynch syndrome is endometrial carcinoma (occurs in 40%-60% of women with the mutation), followed by carcinoma of the ovary (occurs in about 12%-15% of women with the mutation). 20 Based on their study of the evidence, Lindor and colleagues 30 recommend endometrial sampling and transvaginal ultrasonography of the uterus beginning between age 30 and 35. They also recommend transvaginal ultrasonograpy of the ovaries beginning at the same age. We agree with these recommendations, with the caveat that the patient must be fully apprised of the screening limitations for early detection of ovarian cancer, as well as the lack of evidence of a reduction in mortality through endometrial and ovarian screening. • Germline mutation in a mismatch repair gene (most commonly MLH1, MSH2 or MSH6) that segregates in the patient's family (i.e., members who carry the mutation show a much higher rate of syndrome-related cancers than those who do not carry the mutation.) Evidence is lacking, of poor quality, or conflicting, and the balance of benefits and harms cannot be determined
Prophylactic surgery
Colorectal resection (segmental v. subtotal colectomy v. complete proctocolectomy)
For at-risk persons without colorectal neoplasia: generally not recommended, discuss as alternative to regular colonoscopy, with preferences of well-informed patient actively elicited
For persons with a diagnosed cancer or polyp not resectable by colonoscopy, § subtotal colectomy favoured with preferences of wellinformed patient actively elicited
Evidence is insufficient to assess the effects on health outcomes ‡ Insufficient evidence to recommend for or against
Evidence is lacking, of poor quality, or conflicting, and the balance of benefits and harms cannot be determined
Hysterectomy or oophorectomy
Discuss as option after childbearing completed
Good-fair ¶ No recommendation for or against
There is at least fair evidence that the guideline can improve health outcomes but the balance of benefits and harms is too close to justify a general recommendation *Adapted from the US Preventive Services Task Force's 2-tier system to assess the quality of evidence and to assign strength of recommendations in support of each guideline. †While the quality of evidence supporting colon examination is good, the optimal frequency and initiation age have not been adequately studied. ‡Because of limited number or power of studies, important flaws in their design or conduct, gaps in the chain of evidence, or lack of information on important health outcomes. §Resection of a colon neoplasm is therapeutic, not prophylactic. At issue is the extent of resection -if greater than otherwise required by usual surgical considerations, then it carries an element of prophylaxis. Because all persons in this group will be undergoing surgery, there is opportunity to consider prophylactic removal of much or all of the colon. For women, the discussion should include option of having a hysterectomy or oophorectomy at the same time. ¶Defined as evidence that includes consistent results from well-designed, well-conducted studies in representative populations that directly assess effects on health outcomes but the strength of the evidence is limited by the number, quality, or consistency of the individual studies, generalizability to routine practice, or indirect nature of the evidence on health outcomes.
The efficacy of prophylactic hysterectomy and bilateral salpingo-oophorectomy in women who have a Lynch syndrome-related germline mutation is supported by evidence-based findings, and this should be offered as an option for cancer prevention after a woman's family is completed. 36 Screening for more uncommon cancers integral to Lynch syndrome varies depending on specific family history; therefore, this is best addressed by a genetic counselor.
Hereditary colorectal cancer syndromes provide a wealth of opportunities for highly targeted clinical management and prevention. The key to prevention is early diagnosis through a comprehensive family history, followed by germline mutation testing if appropriate, and targeted surveillance and management for patients with mutations.
An extremely useful set of guidelines is that of the National Comprehensive Cancer Network, 37 which can be ordered in print or used as an interactive tool on the Network's website. The network offers colorectal cancer screening guidelines for patients at average or increased risk, including algorithms to assist in recognizing the likely presence of various hereditary colorectal cancer syndromes, deciding if a referral for genetic testing is warranted, and providing management after diagnosis. An advantage of the interactive tool on the website is that physicians can find detailed information and recommendations for the set of variables presented by a specific patient without needing to wade through similar material for the myriad other possible situations.
The American Gastroenterological Association also publishes guidelines that are periodically updated on colorectal cancer screening and surveillance for patients at average and high risk. 38 These provide an excellent background and overview, but, because of their nature, they are not as comprehensive as those by the National Comprehensive Cancer Network.
Lynch syndrome as a model for clinical cancer control
The characteristic clinical features of Lynch syndrome are shown in Box 1. This information is often extremely helpful in establishing a diagnosis and determining who should be tested. For a more detailed discussion, see the articles by Lynch and de la Chapelle. 4, 11 The original Amsterdam criteria 39 were designed to provide uniformity in collaborative research studies and looked at only personal and familial histories of colorectal cancer. When these criteria were determined to be too stringent, the Amsterdam Criteria II 40 were developed. These criteria considered the extracolonic cancers in the Lynch syndrome tumour spectrum, thereby making the diagnosis more specific. Both sets of Amsterdam criteria were used before the development of molecular-based diagnostic tools such as microsatellite instability and immunohistochemistry testing. More recently, the Bethesda Guidelines (Box 2) 41, 42 were developed, which make use of new molecular and pathologic knowledge and have proven to be of even greater use in determining who should receive genetic testing. 43 Microsatellite instability testing is indicated when any one of the guideline criteria is met. 44 Although the original Amsterdam criteria are no longer used to diagnose Lynch syndrome, they have more recently proved useful in the identification of another subset of possibly hereditary colorectal cancers. Lindor and colleagues, 9 as well as some other researchers, have described families that fulfill the original Amsterdam criteria but lack the mismatch repair mutation findings necessary for diagnosis of Lynch syndrome; such families have what is referred to as "familial colorectal cancer type X."
Summary
Increased knowledge of genetics and molecular pathophysiologic pathways holds the promise for the development and timing of screening measures, such as colonoscopy, which may facilitate detection of presymptomatic cancer and potentially a reduction of mortality. Insight into the molecular genetic mechanisms of hereditary cancer syndromes may improve targeted cancer control measures and pharmacologic therapy. Thus, it may one day become possible to select therapy based on genomic or proteomic profiles for targeted molecular-based pharmacologic therapy. Physicians must attain a better grasp of hereditary cancer syndromes and, when more expertise is needed, make appropriate referrals to experienced medical geneticists or a centre with expertise in hereditary cancer. Lives can be saved through cancer prevention using genetic knowledge. Box 2: Bethesda guidelines for testing colorectal tumours for microsatellite instability 41 The following groups of patients should receive testing for microsatellite instability:
• Patients aged less than 50 years with a diagnosis of colorectal cancer.
• Patients with synchronous or metachronous colorectal or other syndrome-associated tumours,* regardless of age.
• Patients aged less than 60 years with colorectal cancer with microsatellite instability-high † histology. †
• Patients with at least 1 first-degree relative with a diagnosis of colorectal cancer or a syndrome-associated tumour* under age 50 years.
• Colorectal cancer or syndrome-associated tumour* diagnosed at any age in 2 first-or second-degree relatives.
*Includes colorectal, endometrial, stomach, ovarian, pancreas, ureter or renal pelvis, biliary tract and brain (usually glioblastoma as seen in Turcot syndrome) tumours, sebaceous gland adenomas and keratoacanthomas in Muir-Torre syndrome and carcinoma of the small bowel. †Presence of tumour infiltrating lymphocytes, Crohn disease-like lymphocytic reaction, mucinous or signet-ring differentiation, or medullary growth pattern.
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